Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Floxuridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TK1 | P04183 | 3/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | TK2 | O00142 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Floxuridine SCHEMBL18561102 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL6270910 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL9155703 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL13674187 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL18573179 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL4939702 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL11564431 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL2050487 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL11563300 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL18597573 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6036 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4711364-A1 | FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND | Pharmaengine, Inc. (TW) | 2026-03-18 | — | — | EP | claimed |
| EP-4701737-A2 | MTA-COOPERATIVE PRMT5 INHIBITOR | Pharmaengine, Inc. (TW) | 2026-03-04 | — | — | EP | claimed |
| US-12544378-B2 | Solid pharmaceutical formulation of PARP inhibitors and use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2026-02-10 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4673448-A1 | SUBSTITUTED NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2026-01-07 | — | — | EP | claimed |
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-12-09 | — | — | US | claimed |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-11-25 | — | — | US | claimed |
| US-4599404-A | BENOYLATION | FUNAI PHARMACEUTICAL IND., LTD. (JP) | 1986-07-08 | — | — | US | claimed |
| EP-0160079-A4 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1986-05-14 | — | — | EP | claimed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | claimed |
| EP-0160079-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1985-11-06 | — | — | EP | claimed |
| EP-0151189-A1 | ANTINEOPLASTIC AGENT | TEIJIN LIMITED (JP) | 1985-08-14 | — | — | EP | claimed |
| EP-0081386-B1 | 5-FLUORO-2'-DEOXYURIDINE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | TEIJIN LIMITED (JP) | 1985-05-29 | — | — | EP | claimed |
| WO-1985001871-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER SHELDON B | 1985-05-09 | — | — | WO | claimed |
| EP-0081386-A1 | 5-Fluoro-2'-deoxyuridine derivatives and a process for the preparation thereof | TEIJIN LIMITED (JP) | 1983-06-15 | — | — | EP | claimed |
| EP-0009882-B1 | 2'-DEOXY-5-FLUOROURIDINE DERIVATIVES, A PROCESS FOR PRODUCING THE SAME AND ANTITUMOR AGENTS COMPRISING THE SAME | FUNAI PHARMACEUTICAL IND., LTD. (JP) | 1982-03-03 | — | — | EP | claimed |
| EP-0009882-A1 | 2'-Deoxy-5-fluorouridine derivatives, a process for producing the same and antitumor agents comprising the same | FUNAI PHARMACEUTICAL IND., LTD. (JP) | 1980-04-16 | — | — | EP | claimed |